Sanofi Announces Market Authorization In Canada For Nuvaxovid, A Non-mRNA Protein-Based COVID-19 Vaccine, To Be Available for Autumn 2026-27 Season

Benzinga Newsdesk www.benzinga.com Positive 83.5%